Revenues from marketed products Cresemba and Zevtera grew 40% YoY to CHF115m contributing to total revenues of CHF134 for Basilea in FY2019. We expect further growth in revenue contributions from Cresemba and Zevtera in 2020E and a greater proportion of cash generative revenues overall. We also anticipate additional upside from Basilea's diversified clinical pipeline. Oncology asset derazantinib is on track for a number of clinical readouts in 2020E and the ongoing US Phase III trial of ceftobip ....
26 Feb 2020
Strong product sales growth, pipeline news flow in 2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong product sales growth, pipeline news flow in 2020
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
26 Feb 2020 -
Author:
Chris Redhead -
Pages:
14
Revenues from marketed products Cresemba and Zevtera grew 40% YoY to CHF115m contributing to total revenues of CHF134 for Basilea in FY2019. We expect further growth in revenue contributions from Cresemba and Zevtera in 2020E and a greater proportion of cash generative revenues overall. We also anticipate additional upside from Basilea's diversified clinical pipeline. Oncology asset derazantinib is on track for a number of clinical readouts in 2020E and the ongoing US Phase III trial of ceftobip ....